Effect of indacaterol on lung deflation improves cardiac performance in hyperinflated COPD patients: An interventional, randomized, double-blind clinical trial

International Journal of COPD

Volumn 10, Issue 1, 2010, Pages 1917-1923

  Santus, Pierachille ^a,b   Radovanovic, Dejan ^a,b   Di Marco, Silvia ^b   Valenti, Vincenzo ^a,c   Raccanelli, Rita ^a,b   Blasi, Francesco ^d,e   Centanni, Stefano ^a,f   Bussotti, Maurizio ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b IRCCS   (Italy)

^c IRCCS POLICLINICO SAN DONATO   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^f SAN PAOLO HOSPITAL   (Italy)

Author keywords

Bronchodilator; Cardiac performance; Echocardiography; Lung deflation; Right ventricular function

Indexed keywords

CARBON MONOXIDE; INDACATEROL; PLACEBO; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; INDAN DERIVATIVE; QUINOLONE DERIVATIVE;

ADULT; AGED; AIRWAY RESISTANCE; ARTICLE; ATELECTASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DECELERATION; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HEART ATRIUM PRESSURE; HEART FUNCTION; HEART LEFT VENTRICLE; HEART PERFORMANCE; HEART SIZE; HUMAN; INSPIRATORY CAPACITY; INTERVENTION STUDY; INTRATHORACIC GAS VOLUME; LUNG ARTERY PRESSURE; LUNG DIFFUSION CAPACITY; LUNG VOLUME; MALE; MITRAL VALVE; OXYGEN SATURATION; PHASE 4 CLINICAL TRIAL; PLETHYSMOGRAPHY; RANDOMIZED CONTROLLED TRIAL; RESIDUAL VOLUME; SINGLE DRUG DOSE; SPIROMETRY; SYSTOLIC BLOOD PRESSURE; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT DURATION; VERY ELDERLY; VISUAL ANALOG SCALE; CLINICAL TRIAL; DRUG EFFECTS; ECHOCARDIOGRAPHY; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; PROSPECTIVE STUDY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; AGED; AGED, 80 AND OVER; AIRWAY RESISTANCE; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DYSPNEA; ECHOCARDIOGRAPHY; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INDANS; INSPIRATORY CAPACITY; LUNG VOLUME MEASUREMENTS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES; TREATMENT OUTCOME;

EID: 84941634352     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S91684     Document Type: Article

References (26)

1. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095-2128.
2. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(10):1005-1012.
3. Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013; 187(4):347-365.
4. Barr RG, Bluemke DA, Ahmed FS, et al. Percent emphysema, air-flow obstruction, and impaired left ventricular filling. N Engl J Med. 2010;362(3):217-227.
5. Watz H, Waschki B, Meyer T, et al. Decreasing cardiac chamber sizes and associated heart dysfunction in COPD: role of hyperinflation. Chest. 2010;138(1):32-38.
6. Grau M, Barr RG, Lima JA, et al. Percent emphysema and right ventricular structure and function: the Multi-Ethnic Study of AtherosclerosisLung and Multi-Ethnic Study of Atherosclerosis-Right Ventricle Studies. Chest. 2013;144(1):136-144.
7. Ather S, Chan W, Bozkurt B, et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol. 2012;59(11):998-1005.
8. Seth HD, Sultan S, Gotfried MH. Role of indacaterol, a once-daily bronchodilator, in chronic obstructive pulmonary disease. J Thorac Dis. 2013;5(6):806-814.
9. Beeh KM, Beier J. Indacaterol, a novel inhaled, once-daily, long-acting beta2-agonist for the treatment of obstructive airways diseases. Adv Ther. 2009;26(7):691-699.
10. Buhl R, Dunn LJ, Disdier C, et al; INTENSITY study investigators. Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD. Eur Respir J. 2011;38(4):797-803.
11. Chapman KR, Rennard SI, Dogra A, Owen R, Lassen C, Kramer B; INDORSE Study Investigators. Long-term safety and efficacy of indacaterol, a long-acting β2-agonist, in subjects with COPD: a randomized, placebo-controlled study. Chest. 2011;140(1):68-75.
12. Dahl R, Chung KF, Buhl R, et al; INVOLVE (INdacaterol: Value in COPD: Longer Term Validation of Efficacy and Safety) Study Investigators. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax. 2010;65(6):473-479.
13. Donohue JF, Fogarty C, Lötvall J, et al; INHANCE Study Investiga-tors. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med. 2010;182(2):155-162.
14. Feldman G, Siler T, Prasad N, et al; INLIGHT 1 study group. Efficacy and safety of indacaterol 150 microg once-daily in COPD: a doubleblind, randomised, 12-week study. BMC Pulm Med. 2010;10:11.
15. Korn S, Kerwin E, Atis S, Amos C, Owen R, Lassen C; INSIST study group. Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study. Respir Med. 2011;105(5):719-726.
16. Kornmann O, Dahl R, Centanni S, et al; INLIGHT-2 (Indacaterol Efficacy Evaluation Using 150-µg Doses with COPD Patients) study investigators. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J. 2011;37(2):273-279.
17. Laforce C, Aumann J, de Teresa Parreño L, et al; INTEGRAL Study Investigators. Sustained 24-hour efficacy of once daily indacaterol (300 μg) in patients with chronic obstructive pulmonary disease: a randomized, crossover study. Pulm Pharmacol Ther. 2011;24(1):162-168.
18. Rudski LG, Lai WW, Afilalo J, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr. 2010;23(7):685-713; quiz 86-88.
19. Cazzola M, Mantero A, Santus P, et al. Doppler echocardiographic assessment of the effects of inhaled long-acting beta2-agonists on pulmonary artery pressure in COPD patients. Pulm Pharmacol Ther. 2007;20(3):258-264.
20. Santus P, Radovanovic D, Henchi S, et al. Assessment of acute bronchodilator effects from specific airway resistance changes in stable COPD patients. Respir Physiol Neurobiol. 2014;197:36-45.
21. Rossi A, Centanni S, Cerveri I, et al. Acute effects of indacaterol on lung hyperinflation in moderate COPD: a comparison with tiotropium. Respir Med. 2012;106(1):84-90.
22. Boissiere J, Gautier M, Machet MC, Hanton G, Bonnet P, Eder V. Doppler tissue imaging in assessment of pulmonary hypertensioninduced right ventricle dysfunction. Am J Physiol Heart Circ Physiol. 2005;289(6):H2450-H2455.
23. Boussuges A, Pinet C, Molenat F, et al. Left atrial and ventricular filling in chronic obstructive pulmonary disease. An echocardiographic and Doppler study. Am J Respir Crit Care Med. 2000;162(2 Pt 1):670-675.
24. Boussuges A, Molenat F, Burnet H, et al. Operation Everest III (Comex ‘97): modifications of cardiac function secondary to altitude-induced hypoxia. An echocardiographic and Doppler study. Am J Resp Crit Care Med. 2000;161(1):264-270.
25. Cazzola M, Page CP, Rogliani P, Matera MG. β2-agonist therapy in lung disease. Am J Respir Crit Care Med. 2013;187(7):690-696.
26. Decramer ML, Hanania NA, Lotvall JO, Yawn BP. The safety of long-acting β2-agonists in the treatment of stable chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2013;8:53-64.